SCCS Finds Three Lash-Growth Prostaglandin Analogues Cannot Be Considered Safe

The Scientific Committee on Consumer Safety concluded that three assessed prostaglandin analogues cannot be considered safe in cosmetics intended to promote eyelash and eyebrow growth. The final opinion, SCCS/1680/25, was adopted on 2 February and published on 10 February 2026.

The assessment covered methylamido-dihydro-noralfaprostal, or MDN, isopropyl cloprostenate, or IPCP, and DDDE, also called Ethyl Tafluprostamide.

Assessed Uses And Safety Concerns

The questions concerned concentrations up to 0.03% MDN, 0.005% IPCP and 0.018% DDDE. The committee highlighted potent pharmacological activity and the absence of acceptable data excluding possible adverse effects on reproduction and development. It considered these concerns particularly relevant to women of child-bearing age.

The SCCS did not identify genotoxicity potential or concern over genotoxic carcinogenicity. It could not exclude non-genotoxic carcinogenicity because experimental carcinogenicity data were absent. These are distinct conclusions.

Scientific Opinion And Existing Legal Duties

The opinion does not itself amend the EU Cosmetics Regulation or create an ingredient-ban deadline. Under Article 10 of Regulation (EC) No 1223/2009, Responsible Persons must keep cosmetic product safety reports up to date with relevant new information.

Existing product-safety and corrective-action duties apply independently of any future ingredient-specific amendment. The opinion does not establish that a particular product can remain on the market.